Maron, R., Vredenburgh, J. J., Desjardins, A., Reardon, D. A., Quinn, J. A., Rich, J. N., … Friedman, H. S. (2008). Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 26(15_suppl), 2074–2074. https://doi.org/10.1200/jco.2008.26.15_suppl.2074

Maron, R., J. J. Vredenburgh, A. Desjardins, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, S. A. Wagner, M. E. Salacz, and H. S. Friedman. “Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2074–2074. https://doi.org/10.1200/jco.2008.26.15_suppl.2074.

Maron R, Vredenburgh JJ, Desjardins A, Reardon DA, Quinn JA, Rich JN, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2074–2074.

Maron, R., et al. “Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2074–2074. Crossref, doi:10.1200/jco.2008.26.15_suppl.2074.

Maron R, Vredenburgh JJ, Desjardins A, Reardon DA, Quinn JA, Rich JN, Gururangan S, Wagner SA, Salacz ME, Friedman HS. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2074–2074.